Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.
Starting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with ...
Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...
CEO Mark Goldsmith highlighted significant advancements in the company's strategic priorities, particularly in the development of RAS(ON) inhibitors targeting RAS-addicted cancers. Progress was made ...
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Revolution Medicines, Inc. is one ...
The latest announcement is out from Adlai Nortye Ltd. Sponsored ADR ( (ANL)). On December 29, 2025, Adlai Nortye Ltd. announced an exclusive licensing agreement granting Jiangsu Aosaikang ...
Zymeworks Inc. recently announced that the U.S. FDA granted Fast Track designation to ZW191, its folate receptor-α–targeting ...
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced ...
Putting patients on renin-angiotensin system (RAS) inhibiting drugs after transcatheter aortic-valve replacement (TAVR) may reverse some of their ventricular damage and cut long-term risks for atrial ...
Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results